Literature DB >> 27656491

Cefoperazone Induced Gastrointestinal Bleeding.

Goutham Reddy Katukuri1, Raja Naga Mahesh Maddala1, Kusugodlu Ramamoorthi2, Manjunatha Hande3.   

Abstract

Cefoperazone is a beta-lactam antibiotic which is frequently used in treating a variety of gram positive and gram negative infections. The chemical structure of cefoperazone contains a side chain of N-methylthiotetrazole which can inhibit vitamin K metabolism resulting in hypoprothombinemia. We report a case of cefoperazone induced coagulopathy manifesting as gastrointestinal bleeding. A Naranjo assessment score of 5 was obtained, indicating a probable relationship between the patient's coagulation function disorder and her use of the suspect drug.

Entities:  

Keywords:  Cefoperazone; Coagulopathy; Vitamin K

Year:  2016        PMID: 27656491      PMCID: PMC5028500          DOI: 10.7860/JCDR/2016/19694.8316

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

1.  Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery.

Authors:  S D Rockoff; M J Blumenfrucht; R J Irwin; R H Eng
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

Review 2.  Pathogenesis of hypoprothrombinemia induced by antibiotics.

Authors:  H Obata; B Iizuka; K Uchida
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  1992       Impact factor: 2.000

Review 3.  Vitamin K deficiency bleeding (VKDB) in early infancy.

Authors:  Martin J Shearer
Journal:  Blood Rev       Date:  2008-09-19       Impact factor: 8.250

4.  Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.

Authors:  M J Shearer; H Bechtold; K Andrassy; J Koderisch; P T McCarthy; D Trenk; E Jähnchen; E Ritz
Journal:  J Clin Pharmacol       Date:  1988-01       Impact factor: 3.126

5.  Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia.

Authors:  Farookh Aziz; Prashant Patil
Journal:  Indian J Pediatr       Date:  2014-10-10       Impact factor: 1.967

6.  Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone. Report of three cases.

Authors:  R Alitalo; M Ruutu; V Valtonen; T Lehtonen; P J Pentikäinen
Journal:  Ann Clin Res       Date:  1985

7.  Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case.

Authors:  B L Strom; R Schinnar; G A Gibson; P J Brennan; J A Berlin
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-03       Impact factor: 2.890

8.  Hypoprothrombinemia associated with cefoperazone therapy.

Authors:  R J Mueller; D Green; J P Phair
Journal:  South Med J       Date:  1987-11       Impact factor: 0.954

9.  Cefoperazone induced gastro-intestinal haemorrhage. A case report.

Authors:  I O Ozen; S Moralioğlu; R Karabulut; B Bagbanci; Z Turkyilmaz; B Demirogullari; K Sonmez; A C Basaklar; N Kale
Journal:  Acta Chir Belg       Date:  2008 Nov-Dec       Impact factor: 1.090

10.  Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature.

Authors:  ZhuYing Cai; Wei Yang; YingYing He; Qingge Chen; ShiQiang Wang; Xuming Luo; Xiongbiao Wang
Journal:  Drug Saf Case Rep       Date:  2016-12
View more
  3 in total

Review 1.  An overview of cephalosporin antibiotics as emerging contaminants: a serious environmental concern.

Authors:  Nilanjana Das; Jagannathan Madhavan; Adikesavan Selvi; Devlina Das
Journal:  3 Biotech       Date:  2019-05-24       Impact factor: 2.406

2.  Fatal Vitamin K-Dependent Coagulopathy Associated with Cefoperazone/Sulbactam: A Case Report.

Authors:  Huan-Rong Hu
Journal:  Drug Saf Case Rep       Date:  2019-06-14

3.  Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report.

Authors:  Shuling Wu; Xiaoyue Bi; Yanjie Lin; Liu Yang; Minghui Li; Yao Xie
Journal:  Infect Agent Cancer       Date:  2022-06-16       Impact factor: 3.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.